P R E S S R E L E A S E

Lelystad, the Netherlands, 12 March 2009

FINAL VERSION OF 2008 ANNUAL REPORT

FORNIX MEETS EXPECTATIONS AND IS AGAIN SET TO DISTRIBUTE FULL NET PROFIT AS DIVIDEND

The year 2008 was the first full year the company operated without the Trading Division, which was sold effective 1 October 2007. Shown below are the results compared to 2007, including the nine months the company operated with the Trading Division. This is followed by the results for 2007, adjusted to the results from continuing operations (Allergy Division and Medical Aids Division) in 2008. After these results, this press release therefore primarily compares the results from continuing operations for the past two financial years.

2008 Financial Year: total results (*including 9 months in 2007 with the Trading Division*)

In millions of EUR (excluding the amounts per share)	**2008**	**2007**	**Increase/decrease**
Revenue	39.8	84.7	(53.0%)
Gross turnover result	32.9	34.0	(3.2%)
Other operating income	0.2	2.2	(90.9%)
Total costs [1])	20.5	18.8	9.0%
[1)] of which costs for allergy research	5.8	4.1	41.5%
Result from operating activities (EBIT)	12.6	17.4	(27.6%)
Net financing income/expenses	1.3	0.8	62.5%
Profit before taxation	13.9	18.2	(23.6%)
Profit after taxation	10.3	14.0	(26.4%)
Earnings per share	EUR 1.39	EUR 2.01	(30.8%)

Continuing operations in 2008 *(excluding the Trading Division sold at the end of 2007)*

In millions of EUR (excluding the amounts per share)	**2008**	**2007**	Increase/decrease
Revenue	39.8	38.1	4.5%
Gross turnover result	32.9	31.5	4.4%
Other operating income	0.2	0.1	100.0%
Total costs [1])	20.5	16.3	25.8%
[1)] of which costs for allergy research	5.8	4.1	41.5%
Result from operating activities (EBIT)	12.6	15.3	(17.6%)
Net financing income/expenses	1.3	1.0	30.0%
Profit before taxation	13.9	16.3	(14.7%)
Profit after taxation	10.3	12.0	(14.2%)
Earnings per share	EUR 1.39	EUR 1.73	(19.7%)

2008 Highlights

- Allergy Division maintained its position as market leader (over 70%) despite challenging market conditions
- Slight increase (3%) in turnover of Allergy Division; EBIT dropped by 13% due to increased research costs
- Medical Aids Division significantly increased turnover by 11%. EBIT remained level as a result of substantial investments in the sales organisation
- Fornix BioSciences' net profit: EUR 10.3 million. This represents a decrease of 14% compared to 2007, due primarily to increased research costs and costs related to the aborted acquisition of Spanish-based company BIAL-Aristegui.
- Acquisition of the selling and distribution rights of the DeCube® anti-bedsore mattresses in Germany
- EBIT decreased by 17.6% to EUR 12.6 million (versus EUR 15.3 million in 2007).
- The Dutch Medicine Evaluation Board (MEB) did not see any reason to reconsider its earlier decision not to provide registration for Oralgen® Grass Pollen based on the results of the pan-European study during the first season of treatment
- Positive results from Oralgen® Grass Pollen study during second season of treatment
- Preparations were made for a new, large-scale, multi-year Oralgen® Grass Pollen research study, the costs of which will be approx. 10 million up to and including the financial year 2012
- Proposal to again distribute the entire EUR 10.3 million as dividend with stock option
- Basic financial position remains strong
- Earnings per share from continuing operations dropped by 20% to EUR 1.39 (EUR 1.73 in 2007)

Outlook for 2009

- Given the uncertain situation regarding the registration of Oralgen® Grass Pollen and the review of the reimbursement scheme for allergen products, Fornix BioSciences is currently not making any projections regarding turnover and profit in 2009.

CEO Cees Bergman, commenting on Fornix' results:
'For Fornix BioSciences, 2009 was a year with two faces. In terms of operations, we nearly met the objectives set, despite the tough market conditions. In spite of increased competition and the relatively large number of patients who had completed the therapy, the Allergy Division succeeded in maintaining its extremely high market share of 70%, and even slightly increased that share. After several years of slight underperformance, the Medical Aids Division did succeed in improving its results in 2008. While we initially had to deal with disappointment with regard to registration, the results of the Oralgen® Grass Pollen follow-up study provide hope for the future. The new three-year confirmatory study to substantiate the medication's long-term efficacy is currently underway, with the first report scheduled to be published at the end of this year. We must accept the related substantial investments in order to be able to achieve our long-term objectives of obtaining the various registrations in the Netherlands and becoming a major player in the European allergy market.'

For Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI), 2008 was an eventful year, in which operations in both the Allergy Division and Medical Aids Division showed strong results and the market share for allergy products remained consistently high despite increased competition and a relatively large number of patients who had completed the therapy.
At the same time, the year saw developments that resulted in a delay in achieving our strategic objectives. The pan-European Oralgen® Grass Pollen study, which, despite having been, in our opinion, successfully completed in early 2008, has not yet resulted in registration. Furthermore, the intended acquisition of Spanish-based allergy company BIAL-Aristegui was cancelled. The positive results of the Oralgen® Grass Pollen follow-up study have since been published, and a three-year confirmatory study is currently underway, which should confirm the long-term efficacy of Oralgen® Grass Pollen. The company's top priority is to obtain registration for Oralgen® Grass Pollen and, subsequently, for Oralgen® Tree Pollen and Oralgen® House Dust Mite.
It will be proposed to again distribute the full net profit for the financial year of EUR 10.3 million to the shareholders, given the company's still excellent liquidity position.

Despite increasingly tough market conditions, the company exceeded the expectations regarding net profit it expressed upon publication of the interim results in August 2008. Net profit from continuing operations totalled EUR 10.3 million, whereas projections last August were for EUR 9.7 million. Additional expenses of a total of EUR 2.5 million arising from additional research costs (EUR 1.7 million) and additional costs related to the termination of negotiations on the acquisition of allergy company BIAL- Aristegui in Spain and Portugal (EUR 0.8 million), announced in March, had a negative effect on the financial results released in early 2008. The operating results of both the Allergy Division and Medical Aids Division remained stable. In 2008, Fornix BioSciences' turnover increased by 4.5% to EUR 39.8 million – slightly lower than the approximately EUR 41 million projected in August 2008.

Turnover and EBIT by division

	Turnover			**EBIT**	
In millions of EUR	**2008**	**2007**		**2008**	**2007**
Allergy Division	**30.1**	29.4		**13.6**	**15.5**
Medical Aids Division	**9.7**	8.7		**2.9**	**2.9**
Trading Division: 9 months	-	46.6		-	**0.1**
Holding company (including discontinued operations)	**-**	-		**(3.9)**	**(1.1)**
Total for Fornix BioSciences	**39.8**	84.7		**12.6**	**17.4**

Allergy Division

Growth in the Allergy Division levelled off, particularly as a result of the relatively large number of patients who had completed their therapy and the lagging performance of the new German division. However, it should be added that the German operations have remained within the objectives of the long-term plan as a result of cost control. The German operations showed a negative EBIT of EUR 0.6 million (in 2007, this was EUR 0.5 million negative) as a result of continued investments in the sales organisation. However, the company's leading position in the Netherlands was consolidated with a market share of over 70%. Turnover in the Allergy Division totalled EUR 30.1 million versus EUR 29.4 million in 2007, representing an increase of 2.6%. EBIT for the division totalled EUR 13.6 million, compared to EUR 15.5 million the previous year; this decline was due primarily to the substantial, EUR 1.7 million increase in costs for clinical research.

Medical Aids Division

The Medical Aids Division's turnover increased by a solid 11% from EUR 8.7 million to EUR 9.7 million. As a result of substantial investments in the sales organisation, which should allow the company to maintain its market share over the next several years, EBIT remained virtually stable at EUR 2.9 million (compared to EUR 2.9 million in 2007).

Clinical Development Plan

In 2008, a key focus was once again the further development and implementation of the Clinical Development Plan (CDP), particularly for Oralgen® Grass Pollen. Following completion of the large-scale pan-European research study conducted in 2007 among 605 hay fever sufferers, the data for the follow-up study have now been released. This data convincingly demonstrates the efficacy of the medication during the second year of treatment, and the results may ensure that the medication will still become eligible for registration.

In 2008, research and development costs for the Allergy Division totalled EUR 5.8 million, representing an increase of 41.5% compared to 2007, when a total of EUR 4.1 million was spent on R&D. This upgrade, which was announced upon the presentation of the interim results, was prompted by the decision during the second half of 2008 to launch another multi-year, pan-European study in order to confirm the long-term efficacy and safety of Oralgen® Grass Pollen. The initial interim results of this confirmatory study are scheduled to be released at the end of the 2009 pollen season. In the years beyond 2009, total investments in the CDP will remain at least an estimated EUR 5 to 6 million annually, and they will continue to have a negative effect on the Allergy Division's financial results.

Modification of reimbursement system
In 2008, the Ministry of Health, Welfare and Sport (WVS) announced its intention to fully review the reimbursement scheme for allergen products effective 1 July 2009. The initial purpose of this review is to ensure that certified allergen products are eligible for reimbursement by including these products in the Medicine Reimbursement Scheme (MRS). In addition, the review provides for regulation of non-certified products. Under certain conditions, these products will also be eligible for reimbursement if no certified alternative is available. Given the special position (i.e. provisional registration) of the three main Oralgen® products (grass and tree pollen and house-dust mites), the company is currently still in talks with the Ministry of Health, Welfare and Sport (VWS) regarding the positioning of these products.

Once again, full profit to be distributed as dividend
At the upcoming Annual General Meeting of Shareholders on 24 April 2009, Fornix BioSciences will propose distributing the full EUR 10.3 million net profit for 2008 to the shareholders as dividend with stock option, just as it did for the two previous years. Despite persistent efforts to make acquisitions related to allergies, the company believes its liquidity position is still strong enough to allocate the full profit in the form of a dividend with stock option. As such, the proposed dividend per share for 2008 will be EUR 1.39, compared to EUR 2.01 for 2007. The interim dividend of EUR 0.65, which was distributed in September 2008, will naturally be deducted from this amount.

Outlook for 2009
Given the uncertain situation regarding the registration of Oralgen® Grass Pollen and the review of the reimbursement scheme for allergen products, Fornix BioSciences is currently not making any projections for turnover and profit in 2009.

Overall results

Turnover
As a result of the divestment of the Trading Division in October 2007, which was still included in the consolidation during the first nine months of 2007 and generated revenues of EUR 47 million, turnover decreased substantially during 2008. Combined turnover for the Allergy Division and Medical Aids Division totalled EUR 39.8 million in 2008, compared to EUR 38.1 million in 2007; this represents an increase of EUR 1.7 million, i.e. 4.5%. In August 2008, Fornix BioSciences still projected that total turnover for 2008 would be approximately EUR 41 million; however, as a result of the declining market for allergy products and the lower-than-expected performance of the German operations, this turnover target was not met.

Gross margin
Gross margin (in the Annual Accounts, this is referred to as 'gross turnover result') totalled EUR 32.9 million for the past financial year, the equivalent of 82.5% of turnover. In a comparison including the Trading Division, this represents a decline of 3.2% compared to the gross margin in 2007, which was EUR 34.0 million. Note, however, that the gross margin for that year still comprised only 40.2% of turnover, which highlights the limited added value of the Trading Division. When we compare the continuing operations for both years, we see that gross turnover result increased by 4.4%: from EUR 31.5 million in 2007 to EUR 32.9 million in 2008. The higher gross margin from continuing operations can be attributed mainly to the higher margins on allergen products and improved performance of the Medical Aids Division.

Other operating income
The other operating income, totalling EUR 0.2 million, is comprised primarily of subsidies and allocation of costs to the Trading Division, which has since been sold.

Costs
Costs for 2008 totalled EUR 20.5 million versus EUR 18.8 million for 2007, representing an increase of EUR 1.7 million, i.e. 9.0%. A comparison of the continuing operations reveals an increase of EUR 4.2 million, i.e. 25.8%, of EUR 16.3 million for 2007 to EUR 20.5 million for 2008. This cost increase can be largely attributed to significantly higher costs related to the Clinical Development Plan: EUR 5.8 million in 2008 compared to EUR 4.1 million in 2007 – an increase of EUR 1.7 million, i.e. 41.5%. In addition, the

increased costs of Artu Biologicals Deutschland (EUR 0.6 million) are also included in the figures. There were also additional costs of EUR 0.8 million related to the terminated acquisition talks with BIAL-Aristegui.

EBIT and net profit

As a result of these higher costs, EBIT dropped by 17.6%: from EUR 15.3 million to EUR 12.6 million. In absolute terms, Fornix BioSciences' profit declined by 26.4%: from EUR 14.0 million to EUR 10.3 million. The 2007 result included sales revenues of EUR 2.1 million from the sale of the Trading Division, a EUR 0.1 negative net profit from the Trading Division and non-operating income with a net effect of EUR 0.2 million. The normalised operating profit for 2007 was EUR 11.8 million. A comparison of continuing operations showed a 14% decline – down from EUR 12.0 million. However, adjusted for the impact of the investment in clinical research (EUR 1.7 million), the start-up loss in Germany (EUR 0.6 million) and the costs related to the aborted acquisition (EUR 0.8 million), net profit for 2008 would have totalled EUR 12.6 million.

Given the company's continued strong liquidity position, the full EUR 10.3 million profit will be distributed to the shareholders in the form of dividend, possibly with stock option.

Financing

Fornix BioSciences is financed to a large degree from shareholders' equity. At year-end 2008, the company's shareholders' equity totalled EUR 51.9 million, i.e. 86% of the balance sheet total (compared to 83% at year-end 2007). In addition, a current account credit facility is in place for a maximum of EUR 4.5 million, which is more than sufficient for the coming year. If Fornix BioSciences is to make use of this facility, it need only satisfy a limited number of covenants and financial ratios.

Other balance-sheet positions

At year-end 2007, stocks totalled EUR 3.7 million (compared to EUR 3.3 million at year-end 2007), representing an increase of 12%. At year-end 2008, the Allergy Division's stocks totalled EUR 2.8 million, compared to EUR 2.2 million at year-end 2007. The debtor portfolio increased by 14.9% to EUR 5.2 million at 31 December 2008 (compared to EUR 4.5 million in 2007), while the payment term for debtors remained the same. The trade liabilities item increased slightly: from EUR 2.5 million at year-end 2007 to EUR 2.6 million on 31 December 2008.

Strong liquidity position

A strong performance by the Allergy Division and Medical Aids Division ensured an excellent liquidity position at year-end 2008. Fornix BioSciences is debt-free and at 31 December 2008, it held EUR 32.0 million in liquid assets (compared to EUR 33.2 million in 2007). Additionally, the company has a total of EUR 2.2 million in own shares in its portfolio (based on the closing price at 31 December 2008); maintaining these strong balance ratios is in line with the strategy of financing suitable, smaller and medium-sized acquisitions from shareholders' equity as much as possible.

Clinical Development Plan

In 2008, research and development costs for the Allergy Division totalled EUR 5.8 million, representing an increase of 41.5% compared to 2007, when a total of EUR 4.1 million was spent on R&D. This upgrade, which was announced upon the presentation of the interim results, was prompted by the decision to launch another multi-year, pan-European study in late 2008 in order to confirm the long-term efficacy and safety of Oralgen® Grass Pollen. The additional investments for this confirmation study total some EUR 10 million. In the years beyond 2009, total investments in the CDP will remain an estimated EUR 5 to 6 million annually, and they will continue to have a negative effect on the Allergy Division's financial results.

Clinical development programme for Oralgen® products
A key component of the Oralgen® Clinical Development Plan was the pan-European clinical Phase III AB0602 study conducted among 605 allergy patients to demonstrate the efficacy and safety of Oralgen® Grass Pollen. The study, which was completed in late 2007, was conducted in 41 clinical centres across seven European countries. Fornix believes that the AB0602 study has demonstrated the efficacy and safety of Oralgen® Grass Pollen. The study included an evaluation of three different dose regimens, and the results showed that administration of the highest of the three doses of Oralgen® Grass Pollen analysed as part of the study can already result in a substantial reduction in allergic symptoms during the first year of treatment, while at the same time the use of other anti-allergy medication can be reduced significantly.

The study showed a clear dose dependency, while various parameters indicating the severity of the allergic symptoms in the highest dose group were reduced significantly compared with the placebo group. In the two lower dose regimens, this statistical requirement was not met during the first year of the study. All dose regimens analysed were safe and were well tolerated.

Preliminary registration maintained
The optimism generated by the positive results of the Oralgen® Grass Pollen study was tempered in mid-2008, when the Dutch Medicine Evaluation Board (MEB) stated that it did not regard the study results as a reason to reconsider its previous rejection of the registration application. Fornix was disappointed about this decision, which it believes was not in accordance with the results of the study. The appeal filed with the District Court of Zwolle in early 2007 against a previous rejection of the registration application is still pending, and until the highest legal authority has rendered a decision on this application, the provisional approval of Oralgen® Grass Pollen will be maintained.

Positive follow-up study during second year of treatment
Upon completion of the AB0602 study, following the 2007 pollen season, the investigators and patients who participated in this study were asked to participate in the ABO602/1 follow-up study, which ran until the end of the 2008 pollen season, and the positive results of this study were released in early 2009. The purpose of the follow-up study was to assess the efficacy and safety of treatment with Oralgen® Grass Pollen during the second season of treatment. The study was designed such that the placebo-controlled, double-blind nature of the previous AB0602 study was maintained. A total of 356 adult patients participated in the follow-up study, all of whom had moderate to severe symptoms of grass-pollen-related rhino-conjunctivitis ('hay fever') in their previous history. The patients were recruited in six European countries: Germany, the Czech Republic, Slovakia, Hungary, Lithuania and the Netherlands.

Conclusion
The results of the AB0602/1 follow-up study demonstrate that the treatment of patients allergic to grass pollen with Oralgen® Grass Pollen, 19,000 BU daily, significantly reduces the allergic symptom score by 47% compared to the placebo, while at the same time the medication score drops by 74% compared with the placebo. The results of the follow-up study also show that the clinical efficacy of Oralgen® Grass Pollen during the second season of treatment still increases significantly in relation to the first season. These results may be a positive factor in the process of obtaining registration for Oralgen® Grass Pollen.

New Oralgen® multi-year study

The company has decided to further expand its research programme with respect to Oralgen® Grass Pollen by launching a new large-scale study during three pollen seasons, in order to confirm the product's long-term efficacy and safety. The initial interim results of this double-blind, placebo-controlled confirmatory study will be released at the end of the 2009 pollen season. Preparations for this study are currently underway.

Other products in the pipeline
The clinical development programmes for the Oralgen® Mites and Oralgen® Tree Pollen products are at a less advanced stage than the development programme for Oralgen® Grass Pollen. A Phase I/II clinical study was launched for both products during the second half of 2008, and depending on the results of these studies, a decision will be made during the course of 2009 regarding the follow-up of the development programme for the products.

Fornix BioSciences' strategy and objectives

Over the past decade, Fornix BioSciences has become the market leader in the Netherlands for sublingual immunotherapeutic products for patients suffering from allergic respiratory diseases. Following the sale of the Trading Division, the company's objective is to focus increasingly on developing these products both nationally and internationally, and the company considers the development and marketing of these products to be its core business. The top priority is currently to obtain registration for the most important allergy products. In addition, registration is a condition to remain eligible for reimbursement.

The Allergy Division is committed to maintaining a leading position in the Netherlands on an organic basis, and aims to enter other European markets as well through major acquisitions and strategic partnerships. Fornix BioSciences' liquidity position allows it to make medium-sized acquisitions; for larger takeovers, i.e. amounts of approximately EUR 35 million and higher, it will attempt to attract alternative financing (i.e. shareholders' equity and loan capital). Intensive pan-European clinical research programmes that should result in the definite registration of the immunotherapy products Oralgen® Grass Pollen, Oralgen® Tree Pollen and Oralgen® Mites will require substantial investments over the next several years.

The company's strategy for the Medical Aids Division will focus primarily on organic growth in the coming years. This means that the previous objective of increasing the division's turnover to approximately EUR 20 million by 2010 through acquisitions and other activities has been abandoned.

In addition, Fornix BioSciences aims to maintain healthy balance sheet ratios, with a solvency ratio (defined as shareholders' equity as a percentage of total capital) of at least 35%. This rate is currently 86% (compared to 83% in 2007), thereby allowing ample opportunities for acquisitions and therefore also for improvement of the risk profile.

Results by division

Allergy Division

(in millions of EUR)	**2008**	2007	2006
Net turnover	**30.1**	29.4	26.4
EBIT	**13.6**	15.5	15.1
Number of employees at 31 December	**91**	87	82

The Allergy Division is comprised of subsidiaries Artu Biologicals Europe and Artu Biologicals Deutschland. Operating in the Dutch and German markets, these divisions are dedicated to scientific research into, and the development and sale of, diagnostic and therapeutic allergen products for patients suffering from allergic respiratory diseases. For many years, this has been Fornix' most profitable division, producing premium allergy products such as Oralgen® and the veterinary allergy product Artuvetrin®, which has already received registration. A detailed Clinical Development Plan is in place for the further development of these products and their eventual registration that will require substantial investments over the next several years.

In 2008, employing a total of 91 people (compared to 87 in 2007) and facing slightly increased competition and a relatively large number of cured patients whose treatment has been completed, the division had a turnover of EUR 30.1 million (compared to EUR 29.4 million in 2007), representing an increase of 2.6% and an EBIT of EUR 13.6 million (compared to EUR 15.5 million in 2007). The lower-than-expected EBIT was clearly the result of the significantly higher costs for clinical research into the efficacy of the various allergen products for the purpose of obtaining registration.

In 2008, research and development costs totalled EUR 5.8 million. This was contrary to projections, according to which costs would remain at the 2007 level of EUR 4.1 million. Without the impact of these investments, EBIT would be EUR 15.3 million.

The relatively lower increase in turnover compared to previous years was anticipated, and was primarily the result of a slight decline in sales of the Oralgen® immunotherapeutic product. However, turnover still increased slightly in the company's main market the Netherlands, partly as a result of higher margins. Turnover for the key veterinary allergy product Artuvetrin® increased as well, accounting for a larger portion of the profit, as did turnover for the other allergy products and nutritional supplements.

Status update on Oralgen®
The number of new patients using Oralgen® immunotherapeutic products declined slightly in 2008, and growth in this market was limited in the past year. However, the number of patients who completed the treatment after an average of 3 to 5 years was relatively high in 2008 and the company faced increased competition. It is also estimated that failure to obtain registration for Oralgen® Grass Pollen based on the clinical research conducted in 2007 has led to slight hesitance among both GPs and patients; nevertheless, Fornix BioSciences' market share in the Netherlands remained higher than 70%, and market share even increased slightly during the last quarter, after the launch of the new formula. In the year under review, we were committed to further improving therapy loyalty among patients, particularly during the first year of use, as this is considered a crucial factor in whether or not the full treatment is completed.

Other products
Sales in the Netherlands of the registered subcutaneous allergy product Pollinex® stabilised in 2008 due to increased focus on marketing in the recent period.
The veterinary allergy activities increased by 12% in 2008 (compared to 26% in 2007), thereby also contributing to total profit. After the successful years 2006 and 2007, sales of the Artuvetrin® Serum Test increased significantly in both the Netherlands and the United Kingdom, which also led to an increase in

the sale of Artuvetrin® Therapy.
In 2008, sales of the Artuvetrin® Serum Test were good, increasing by more than 50%. This was due primarily to the continued increase in sales in the Netherlands, the United Kingdom and France.
The sale of Fornix' own, Netherlands-produced nutritional supplement Kerutabs® and Kerulac®, designed for patients suffering from lactose intolerance, Increased by more than 11% in 2008 compared to 2007. The bulk of this growth is due to a strong 19% increase in sales in the Netherlands.

Artu Biologicals Deutschland
During its first full year as part of Fornix BioSciences, Artu Biologicals Deutschland generated a turnover of EUR 1.4 million, compared to EUR 0.7 million in the seven months following the acquisition of the operations of Rölke Pharma in 2007. As indicated in the 2007 annual report, EBIT remained negative in 2008, totalling EUR 0.6 million negative. This was the result of substantial investments in the sales and marketing organisation.
Operations were expanded in late December 2008 with the acquisition of the selling and distribution rights of the DeCube® anti-bedsore mattresses, which are distributed in the Netherlands through the Medical Aids Division. Turnover for these mattresses is approximately EUR 1 million, and the rights were bought for EUR 1.25 million in cash. In 2008, Artu Deutschland furthermore acquired the exclusive selling rights for Germany of Scarban®, an innovative medical silicone gel sheeting for the prevention and treatment of scars. In the Netherlands, this product is also distributed by the Medical Aids Division.

Strategy and outlook for 2009: Allergy Division
With respect to Oralgen®, 2009 will be a year in which our market and service strategies will be enhanced with new elements with respect to GPs, specialists and – indirectly – patients. There will again be increased investments to improve therapy loyalty.
The positive results of the follow-up study into the efficacy and dosage of Oralgen® Grass Pollen may contribute to further acceptance of this form of immunotherapy among GPs and specialists, as well as to ensuring that registration is obtained. As long as no registration is granted for Oralgen® Grass Pollen in the Netherlands, marketing and sales activities for Igevac® (Germany version of Oralgen) will remain limited. The main focus in 2009 will be on the sale of the DeCube® anti-bedsore mattresses and the Scarban® products. The objective is to achieve a break-even EBIT in 2009.

Medical Aids Division

(in millions of EUR)	**2008**	**2007**	**2006**
Net revenue	**9.7**	8.7	8.4
EBIT	**2.9**	2.9	2.6
Number of employees at 31 December	**26**	25	26

The Medical Aids Division, which consists of the medical company Laprolan, acquired in 2006 and based in Beuningen, the Netherlands, has the exclusive selling rights in the Netherlands for a wide range of medical aids, and for several products it also has the European selling rights. The products in question are related to urological and stoma care, wound and scar treatment and anti-bedsore treatment. The products are sold to a variety of institutions (including hospitals and nursing homes), as well as to pharmacies, medical retailers, wholesalers and homecare organisations.

Turnover increased by 11% from EUR 8.7 million in 2007 to EUR 9.7 million in 2008. EBIT remained at the same level as in 2007: EUR 2.9 million. Despite the measures implemented, margins remained at a healthy level. EBIT remained the same as a result of additional investments in marketing activities, including a reorganisation of the full sales force and the implementation of a new CRM system. The increase in turnover is promising; this can be directly attributed to the new management and the measures to recover turnover growth, which were implemented back in late 2007.

Sales in DeCube® anti-bedsore mattresses were boosted by an order from a university medical centre, while IQ-Cath® and PolyMem® showed excellent sales volumes as well. Partly as a result of increased competition, sales of the Scarban® scar bandage was slower, which also applies to the washable

underblankets. Sales prospects for all product groups are good. The launch in 2009 of a new range of stoma products should ensure that Laprolan will become a major player in this segment.

Substantial efforts were made in the past financial year in implementing new sales and marketing strategies, expanding the sales force and revitalising it by appointing three specific sales teams. In addition, the company's product range was carefully reviewed. In 2008, a newly implemented sales and marketing strategy has boosted sales of a number of priority products.

Strategy and 2009 outlook for the Medical Aids Division
Laprolan has a solid basis for growth for the coming years. With an increased focus on customers, a good strategy for product selection and an improved market position through clear communications, Laprolan faces the current financial year with confidence. The division aims to increase turnover organically and improve EBIT, and its strategy will also continue to be based on organic growth through further market penetration and the launch of new products. One factor that remains uncertain is the reimbursement policy pursued by the Dutch government and health insurance companies, which is geared towards cost reduction.

Fornix BioSciences' Outlook for 2009

Given the uncertain situation regarding the registration of Oralgen® Grass Pollen and the review of the reimbursement scheme for allergen products, Fornix BioSciences is currently not making any projections for turnover and profit in 2009.

For the Allergy Division, Fornix BioSciences hopes that the Dutch Medicine Evaluation Board will again render a decision in 2009 regarding the registration of Oralgen® Grass Pollen, following submission in the first quarter of 2009 of the positive results of the Oralgen® follow-up study.

E N D O F P R E S S R E L E A S E

For further information, please contact:

Fornix BioSciences N.V.
C.L. Bergman, CEO, Fornix BioSciences N.V.
Tel. +31 (0) 320 26 77 99
Website: **www.fornix.nl**

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables. Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carried on by two divisions, which in turn are made up of operating companies.

The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the effectiveness of the various products.

The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.

Annexes